Dr Ajay Aggarwal is a Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Trust, London. He has Honorary appointments at King’s College London, the London School of Hygiene and Tropical Medicine and The MRC Clinical Trials Unit, London. His main research areas are health services research, clinical epidemiology and global health. Since 2013, he has been the Oncology Coordinator for the National Prostate Cancer Audit, based at the Royal College of Surgeons of England.

As part of this work, he developed the first-ever national radiotherapy outcomes public reporting program. In 2017, he completed a NIHR PhD Fellowship at The London School of Hygiene and Tropical Medicine exploring patient choice and the role of NHS hospital competition in the adoption of high cost medical devices for cancer treatment using quantiative and qualitative research methods. He has worked at the World Health Organisation in Geneva and has ongoing projects in Ghana, Botswana, and Tanzania aimed at building radiotherapy capacity and research capabilty. He was recently awarded in collaboration with the MD Anderson Cancer Centre, USA, a Wellcome Trust Digital Innovator Award, to use Artificial Intelligence to automate radiotherapy treatment planning for the treatment of urgent and emergency presentations of advanced cancers. He has previously gained a BSc in Management at Imperial College London, a MSc in the Science of Cancer from The Institute of Cancer Research and a MSc in Health, Population and Society from The London School of Economics where he undertook research into complex health systems and behavioural public policies.

Christopher Booth MD FRCPC is a Medical Oncologist and Health Services Researcher at Queen’s University in Kingston, Canada. He is a Professor of Oncology and holds the Canada Research Chair in Population Cancer Care. Dr. Booth studied medicine at Queen’s University and did postgraduate training in Internal Medicine and Medical Oncology at the University of Toronto. Upon completing his clinical training he spent two years as a research fellow with the NCIC Clinical Trials Group. In his clinical practice he provides care to patients with gastrointestinal and urologic cancers.

Dr. Booth has an active program in population-based cancer research. The focus of his research program is to evaluate the quality of care delivered to patients in routine clinical practice and the effectiveness of new therapies in the general population. In 2016 Dr. Booth spent a sabbatical as a visiting scientist at the Regional Cancer Centre in Trivandrum, India. He continues to work closely with colleagues in India on various projects to improve accessibility and quality of cancer care. Dr. Booth serves as an Advisor (Implementation Research) to the National Cancer Grid of India. As a junior investigator he was awarded an inaugural Cancer Care Ontario Chair in Health Services Research. Dr. Booth has published over 200 peer-reviewed manuscripts with first or senior author papers in Nature, JAMA, BMJ, Lancet Oncology, and Journal of Clinical Oncology. He has served as research supervisor for more than 25 trainees.

Marc Buyse holds a ScD in biostatistics from the Harvard School of Public Health (Boston, MA). He worked at the EORTC in Brussels and at the Dana Farber Cancer Institute in Boston.

He is the founder of the International Drug Development Institute (IDDI) and of CluePoints, two biostatistical service organizations based in the US and Europe. His interests include clinical trial design, meta-analysis, validation of biomarkers and surrogate endpoints, statistical methods in oncology, statistical detection of errors and fraud, statistical monitoring of clinical trials, and medical data sharing (http://publicationslist.org/marc.buyse ).

Girish Chinnaswamy completed his medical school and post graduate training in paediatrics at Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Pondicherry. He further underwent subspeciality training in paediatric and adolescent oncology at the Royal London and Newcastle Upon Tyne Hospitals in the United Kingdom.

He subsequently pursued research in paediatric cancer pharmacology at the Northern Institute of Cancer Research, Newcastle University studying the pharmacokinetics and pharmacogenomics of anticancer drugs in Children. He has previously worked as a faculty in paediatric oncology at Christian Medical college hospital Vellore and is presently working as a consultant at Tata Memorial Hospital. His special interests are paediatric neuro-oncology and bone tumors in children.

Dr David Collingridge has been Editor-in-Chief of The Lancet Oncology since March 2002 and is also the Publishing Director for The Lancet’s specialty journals. Prior to his appointments at The Lancet, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK. Dr Collingridge has won several awards for projects focused on cancer control in low-to-middle income countries; has published numerous peer-review articles, editorials, opinion pieces, and news reports; and has co-authored a text book on radiobiology. He currently also holds the position of Clinical Associate Professor of Radiation Medicine at Hofstra/Northwell Health, Lake Success, NY, USA.

Chris Frampton is Professor, Biostatistics, Department of Medicine/Psychological Medicine, University of Otago, and Director of a statistical consultancy company based in Christchurch, New Zealand.

In addition, he is the statistical representative on New Zealand’s regulatory committees - the Standing Committee on Therapeutic Trials, Medicines Adverse Reactions Committee, and Medicines Assessment Advisory Committee - and on a number of national and international data safety monitoring committees for ongoing randomised controlled trials. Professor Frampton has a specific interest in the design, conduct and analysis of phase I, II and III randomised controlled trials. With over 30 years of experience in biostatistics consultancy as applied to a wide range of clinical disciplines, he has co-authored over 700 peer reviewed publications.

Durga Gadgil is currently a consultant with the Tata Memorial Administrative and Research Council (TRAC). She is the chief coordinator for the two-year MSc in Clinical Research course conducted by the Tata Memorial Centre under the Homi Bhabha National Institute. She is also a GCP Trainer and conducts workshops and seminars for the same. Besides, she is instrumental in setting up the National Cancer Grid Contract Research Organization (NCG CRO) at TMH, which monitors NCG funded, multicentric studies carried out in India.

She has 31 years of experience in the pharmaceutical industry and retired in November 2015 as Area Head, Asia Pacific, Regional Medical Monitoring Organization, Pfizer. In this role, she was the line manager for medical monitors based in Australia, India, Singapore, Hong Kong, China, Korea, Taiwan and Philippines. The team was responsible for monitoring all global studies from Phase 2 to 4 for medical aspects, ensuring patient eligibility, protocol adherence, data integrity and quality, in compliance with local and global ethical principles.

Durga is a certified NABH assessor for NABH Accreditation Standards for Clinical Trials (Ethics Committee, Investigator, Clinical Trial Site)

During her career span of 30+ years, she has worked in many pharmaceutical companies, all MNCs and one India company. She has experience in all fields related to a medical doctor’s role in the industry, like medico-marketing support, regulatory activities, pharmacovigilance and safety reporting, clinical operations, medical monitoring, auditing and training.

Allan Hackshaw is Professor of Epidemiology & Medical Statistics at University College London, and Deputy Director of the Cancer Research UK & UCL Cancer Trials Centre, one of the largest cancer trials units in the UK. He has over 26 years’ experience in the design, conduct and interpretation of clinical trials (phase I-III), observational studies (cohort and case-control) and systematic reviews/meta-analyses: for prevention, screening or treatment. The main areas of research have been cancer; antenatal & cancer screening; and tobacco and health..

He has been a key co-investigator on successful grant funding applications (>£80 million in total), and published more than 150 articles in journals and book chapters, plus sole or first author of four textbooks. He leads courses or modules on postgraduate courses (evidence-based medicine/clinical trials) at UCL and London School of Economics. He has been a member of national and international scientific grant funding and data monitoring committees. In 2013 he was named as one of the top 40 academic role models in biomedicine at UCL.

Mahesh (Max) Parmar is a Professor of Medical Statistics and Epidemiology and Director of the MRC Clinical Trials Unit at UCL and the Institute of Clinical Trials and Methodology at University College London.

Until 2012 he was an Associate Director of the National Cancer Research Network since its inception in 2001, an organisation which more than tripled the number of patients going into cancer studies in England. Max joined the MRC in 1987.  He has more than 300 publications in peer reviewed journals, many of which have had direct impact on policy, clinical practice and improving outcomes for patients. The Unit he directs is at the forefront of resolving internationally important questions, particularly in infectious diseases and cancer, and also aims to deliver swifter and more effective translation of scientific research into patient benefits. It does this by carrying out challenging and innovative studies and by developing and implementing methodological advances in study design, conduct and analysis.

C S Pramesh is the Director of the Tata Memorial Hospital and a thoracic surgeon at the Tata Memorial Centre, the largest cancer centre in India. He is also a member of the Clinical Research Secretariat of the hospital and the convener for the National Cancer Grid, a large network of 177 cancer centres in India. In the latter role, he works extensively on eliminating disparities in cancer care by enabling uniform standards of cancer care, promoting equity in access to care, rational use of healthcare resources and promoting multicentric collaborative research.

His primary clinical areas of interest include minimal invasive surgery and innovative treatment options in the management of esophageal and lung cancer. He is the Principal Investigator in several investigator-initiated research studies including randomised trials on cancer screening, surgical techniques, and neoadjuvant and adjuvant treatment of thoracic cancers. Professor Pramesh has strong interests in clinical trial designs, surgical trials, biostatistics and promoting collaborative research.

He is passionate about promoting training of early career physicians and surgeons in clinical research methods and conducts several formal and informal courses on clinical research methodology, biostatistics and scientific writing.

Professor Arnie Purushotham has been a Consultant Academic Surgeon for 24 years having worked in Glasgow, Cambridge and London. He is Professor of Breast Cancer at King’s College London and Consultant Surgeon at Guy’s and St Thomas NHS Foundation Trust in 2005. He is the Director of King’s Health Partners Comprehensive Cancer Centre, Medical Director Tata Trusts Cancer Care Program and Senior Clinical Advisor to Cancer Research UK.

As a scientific researcher for the last 27 years, Professor Purushotham’s goal has been to drive high quality clinical and translational research that directly impacts on cancer patients. Key areas of research are patterns of metastatic spread, pathophysiology of lymphoedema, sentinel lymph node biopsy, novel optical intra-operative imaging, window of opportunity trials and cancer outcomes. His specific areas of expertise include study design, ethics and regulatory permissions, research governance, user involvement, window of opportunity studies and randomized controlled trials

Dr Ramakrishnan is a surgical oncologist (gastrointestinal oncology) and is one of the founding members of the South Indian Oncology Group (SIOG), a multicenter collaborative group formed to promote cancer research in India. He has been awarded the Global Challenges Research Networking Fund Grant by the Academy of Medical Sciences, UK for the project titled ‘Large bowel microbiome disease network - Creation of a proof of principle exemplar in colorectal cancer across three continents’. He has several publications in national and international journals.

Priya Ranganathan works as Professor of Anesthesiology at the Tata Memorial Centre, which is a tertiary-level cancer centre in Mumbai, India. She deals mainly with anesthesia for thoracic surgical procedures especially esophageal and lung resections.

She has a keen interest in clinical research methods and biostatistics and has been faculty on several short courses on these topics. She coordinates a Masters degree in Clinical Research at the Tata Memorial Centre. She is a member of the Institutional Review Board at Tata Memorial Hospital and is editor of the biostatistics section for the journal ‘Perspectives in Clinical Research’.

Priya completed her medical training at the King Edward Memorial Hospital, Mumbai and a fellowship in Clinical Anesthesia at the Singapore General Hospital..

Prachi Patil is a Professor in the Department of Digestive Diseases and Clinical Nutrition at the Tata Memorial Centre, Mumbai, India. She completed her Gastroenterology training at the Tata Memorial Hospital. Her areas of interest are gastrointestinal cancers, therapeutic endoscopy and clinical nutrition. She is an ACORD alumnus (2010). She has been a member of the Institutional Review Board as well as the data and safety monitoring sub-committee at Tata Memorial Hospital. She has been a PI for several investigator-initiated as well as industry sponsored clinical trials.

Manju Sengar [MD (Medicine), DM (Medical Oncology)] is Professor, Adult hematolymphoid disease management group, Medical Oncology at the Tata Memorial Hospital, Mumbai. Dr Sengar completed her training in Medical Oncology from All India Institute of Medical Sciences, New Delhi.

She has done her post graduate diploma in clinical trials from London School of hygiene and tropical medicine (external programme). She is an ACORD alumnus. She is a recipient of American Society of Hematology visitor training program fellowship at Duke University, Durham. Her main areas of clinical research are non Hodgkin lymphomas in HIV/AIDS and adult acute lymphoblastic leukemia. She is the principal investigator for several investigator-initiated studies and has participated in industry sponsored multi-centre clinical trials.

Dr. Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD in London, England and his MD at University of Pennsylvania, Philadelphia, USA. His clinical research investigates methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licensing of previous (mitoxantrone) and current (docetaxel) standard chemotherapy. His laboratory research evaluated effects of the tumour microenvironment on outcome of cancer therapy.

Dr. Tannock is an editor of the Basic Science of Oncology textbook, soon to be in its 6 th edition, that is used by trainees in all branches of oncology. He was a member of the Board of the American Society of Clinical Oncology (ASCO) from 2001-2004, and was chair of the scientific audit committee of the European Organisation for Research and Treatment of Cancer (EORTC) and a member of the EORTC Board from 2011-2017.  Dr Tannock was the first non-European to receive the European Society of Medical Oncology (ESMO) award (2012) and he received the Allan Lichter visionary leader award from ASCO in 2019. Dr. Tannock received an honorary degree (DSc) from London University, UK in 2009, and was appointed a Member of the Order of Canada in 2013.

Shivakumar Thiagarajan graduated from KIMS, Bangalore. After which he did his post-graduation in Otolaryngology from the Indian AirForce Hospital, Bangalore.

He further underwent sub-speciality training in Head and Neck Surgical Oncology from Kidwai Memorial Institute of Oncology, Bangalore and Tata Memorial centre, Mumbai. He was actively involved in both clinical and translational research during his training. He has worked as a faculty in both Otolaryngology and Head and Neck surgical oncology, during which he has been part of various research projects. He is presently working as a faculty in the department of Head and Neck surgical oncology, Tata Memorial Centre, Mumbai, India. His primary clinical interest is in the management of oral, thyroid and skull base malignancies.

Matt Sydeshas been designing, conducting, analyzing, reporting & disseminating clinical trials, and seeking to improve them, for more than 25 years as a trial manager and then statistician.

 His particular areas of interest include: Unleashing potential of healthcare systems data (electronic health records, routinely-collected healthcare data) to support trials; Designing academic trials for regulator use & submission; Efficient & proportionate monitoring; Implementing novel designs, including multi-arm multi-stage platform trials; Function & conduct of trial oversight committees; Appropriate data sharing of clinical trial data; Dissemination of trial results.

 Matt served >15 years as a trial statistician and project lead on the STAMPEDE trial (SCT’s Trial of the Year 2018), a multi-arm multi-stage platform protocol that repeatedly delivered internationally practice-changing results. He has delivered trials that involved international collaboration in rare & common diseases.

Yogesh is a public health practitioner, researcher and a neurologist trained in India and the United States. He has experience of working on micro to macro aspects of health. Twelve years ago, he left his job in the US to work with rural and indigenous communities in central India that have limited access to care. His public health research has identified stroke and cancers as major public health problems in rural central India. He was instrumental in setting up a mortality surveillance system, conducting epidemiological studies on stroke and setting up a rural population-based cancer registry in the resource poor Gadchiroli district of Maharashtra in central India. He also led a cluster randomised controlled trial of a community-based intervention to reduce deaths due to stroke. He believes that data poverty hampers progress in improving the health of the rural and indigenous people. He currently works at Sangwari, a non-government organization in Surguja district of northern Chhattisgarh. Here, he is involved in implementing evidence-based care for sickle cell disease and other NCDs in the public health system. Yogesh serves on several technical committees of the Indian Council of Medical Research, is a member of the advisory group for the cause of death determination system of the Government of India, Sickle Cell Disease Technical Advisory Group of the National Health Mission Chhattisgarh and the Brain Health Initiative of the Government of Karnataka. He has published more than 60 research papers in international and national journals including in the Lancet, Lancet Global Health, Lancet Regional Health and Stroke. He is a recipient DBT/Wellcome trust fellowship in public health and the Bruce Shoenberg International Award in Neuroepidemiology by the American Academy of Neurology.

Xavier Paoletti is a professor of biostatistics at the University of Versailles St Quentin and at the Institut Curie, a cancer center, in Paris, France; he is a member of the INSERM U900 research unit dedicated to the development of statistical methods for clinical trials integrating biomarkers. After a phd on early phase clinical trials, Xavier had several positions at the EORTC, at Bichat university hospital then at the French NCI and finally in two leading cancer centers, Institut Curie and Gustave Roussy. His main interests are in the methods for dose finding trials, the designs of trials evaluating personalized medicine and the validation of surrogate endpoints. He is involved with Koji Oba in the secretariat of the GASTRIC collaboration for performing meta-analyses in gastric cancers and he coordinate the gynecology cancer inter group (GCIG) meta-analysis with Dr Ros Glasspool for performing meta-analyses in ovarian cancer.

Dr Balu Krishna Sasidharan is Professor of Radiation Oncology at CMC, Vellore. His research interests include upper GI, Head and Neck, Thorax, Prostate Cancer Research, Radiomics – Artificial Intelligence, Function Sparing Radiation, Mouse Tumour models, Immunotherapy and Radiation.

Michael Brada was a Professor of Radiation Oncology at the University of Liverpool and an Honorary Consultant in Clinical Oncology at Clatterbridge Cancer Centre; previously Professor of Clinical Oncology at the Institute of Cancer Research and the Royal Marsden Hospital in London. He is a leading international expert in neuro-oncology and thoracic oncology with a particular expertise in the development, evaluation and implementation of new technologies. As an acknowledged national and international expert he served as the President of the European Association of Neuro-oncology (EANO), Chairman of the NCRI Brain Tumour Clinical Studies Group and as the President of The European Society of Therapeutic Radiation Oncology (ESTRO), a leading position in European radiotherapy. He was elected an honorary member of a number of national radiation oncology societies, a founding Fellow of European Academy of Cancer Sciences and was the Tata Memorial Orator in 2014. He received the Lifetime Achievement Award of ESTRO. He published benchmark studies of technical aspects and clinical outcome of stereotactic radiotherapy and key studies of late toxicity of cranial irradiation. Has been involved in the evaluation of chemotherapy and radiotherapy in glial tumours including initial studies of Temozolomide. In the last decade the principal focus has been on lung cancer, developing and testing novel technologies including motion management techniques, high precision irradiation and population studies on lung cancer radiotherapy. He was also involved in evaluation of novel technologies through systematic reviews and meta-analyses, which have not infrequently generated heated debates. Throughout his career he had a deep interest in improving methods of care and follow-up of cancer patients with studies resulting in changes to clinical practice. He authored and coauthored more than 270 peer-reviewed articles, editorials, and book chapters.

After graduating from the University of Pune, India, Dr Khot trained in Internal Medicine in India and the UK, where he qualified as a Member of the Royal College of Physicians. He completed training in laboratory and clinical Haematology in London, UK, obtaining a Fellowship from the Royal College of Pathologists. This was followed by a clinical research fellowship involving early phase clinical trials in cell therapies and myeloma at the Peter MacCallum Cancer Centre. Dr Khot has published in international journals and presented in international conferences in his fields of interest of cell therapies, haematopoietic progenitor cell transplantation, myeloma and early phase clinical trials. He currently works as a Consultant Haematologist at the Peter MacCallum Cancer Centre and Bendigo Health and is an investigator in all phases of clinical trials involving novel agents in myeloma and advanced haematologic malignancies.

Dr. Aju Mathew is an American Board-certified medical oncologist and hematologist in Kochi. He is currently working at the MOSC Medical College (a rural medical college) and the Ernakulam Medical Centre (a private urban centre). He is also a senior medical advisor for the Karkinos Healthcare, a cancer care start-up aiming to set up distributed cancer care centres across India. He is also a consultant at the Trivandrum Institute for Palliative Sciences, a WHO centre for palliative medicine. Previously, he was an attending physician at the National Cancer Institute-designated Markey Cancer Center of the University of Kentucky. He was also the Co-Director of the Hematology/Oncology fellowship training program. After graduating in medicine from the Government Medical College Trivandrum in Kerala, he has attained further training in Cambridge University (epidemiology) in England, Karolinska Institute (molecular biology) in Sweden and University of Pittsburgh (residency in internal medicine and fellowship in hematology/medical oncology). He has published in major high impact journals in the field of medicine. He has also received awards from the American Society of Clinical Oncology and American Association of Cancer Research for his scholarly work.

Dr Kang is responsible for leading the newly formed team and executing against its

three strategic focus areas: Enteric & Diarrheal Diseases, Diagnostics and Genomics,

Epidemiology & Modelling. In addition to serving on the foundation’s Scientific Advisory Committee, she has been a Professor in the Division of Gastrointestinal Sciences, Christian Medical College (CMC) in Vellore, India. She is a physician scientist working on vaccines and public health, particularly focused on children and enteric infectious disease in India. Her research ranged from water and sanitation to vaccines and nutrition, and her team is one the strongest multidisciplinary research groups in India, internationally recognized and consistently funded by the Wellcome Trust and the National Institutes of Health, and

more recently, the foundation.

While based at CMC for most of her career, she also worked for the Government of India, leading and building India's first translational health science institute. She has served on WHO headquarters, WHO Southeast Asia and Indian committees related to vaccines, covering policies and introductions, and in more technical areas, safety, new product development, modelling and biological standardization. She has been a mentor and guide for women at work and outside of work.

Duncan Gilbert graduated from the University of Cambridge in 1997 and trained in Clinical Oncology in Sussex and at the Royal Marsden Hospitals. As part of his training, he undertook a PhD in the molecular biology of testicular cancer at the Institute of Cancer Research and also spent 6 months working at the Bhaktapur Cancer Hospital, Nepal. He is now a Consultant Clinical Oncologist treating patients with pelvic cancers at the Sussex Cancer Centre in Brighton, Sussex and an Associate Professor of Cancer and Clinical Trials at MRC Clinical Trials where he is the chief investigator for REFINE, testing extended intervals of immune checkpoint inhibitors in renal cancer and melanoma, and has senior roles within the STAMPEDE and Add Aspirin trial teams.

Dr. Berry is the Chief and Medical Director of the Carlo Fidani Cancer Centre and the Cancer Program at Trillium Health Partners in Mississauga, Ontario, Canada. He is the Regional Vice President for Ontario Health - Cancer Care Ontario and an Adjunct Professor of Oncology at Queen’s University.

Dr. Berry’s clinical specialty is gastrointestinal cancer.  He is a clinical trialist who has led and participated in key trials for the Canadian Cancer Trials Group and is the Co-Chair of the Gastrointestinal Disease Site Group of the Cancer Cancer Ontario Program in Evidence Based Care. 

Dr. Berry is a medical educator who has previously served as Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology.  He is the Co-Director of Education for the Queen’s Global Oncology Program and one of the co-founders of OncologyEducation.com. 

His other academic interest is the bioethical issues surrounding the care of people with cancer. He is a former member and ethics advisor to the pan-Canadian Oncology Drug Review Expert Review Committee and has served on the American Society of Clinical Oncology Ethics Committee.

Dr. Ginsburg is a medical oncologist and global women’s health researcher with nearly 20 years of experience in global cancer prevention and control. In 2022 she joined the U.S. National Institutes of Health, as a Senior Advisor for Clinical Research at the National Cancer Institute’s Center for Global Health. Formerly based at the University of Toronto, Canada, she was a Medical Officer at the World Health Organization (WHO) Geneva, Switzerland (2015-2016) where she provided technical support on cancer control for countries in Africa, Asia, the Middle-East, and Latin America, and contributed to the development of normative guidance on cancer early detection and screening.

Dr. Ginsburg has since served as an ad hoc consultant to WHO, UNFPA, and IAEA-Programme of Action for Cancer Therapy (PACT). From 2017-2021 she was the Director of the High-Risk Cancer Genetics Program at the Perlmutter Cancer Center, an NCI Designated Comprehensive Cancer Center, and an Associate Professor in the Departments of Population Health and Medicine at NYU School of Medicine. Prior to joining the NCI, in 2021 Dr. Ginsburg was a Senior Visiting Scientist in the Cancer Surveillance Unit at the International Agency for Research on Cancer (IARC), the WHO’s specialized cancer agency. Her research is focused on improving equitable access to breast and cervical cancer prevention and control. She has authored >100 peer-reviewed publications and over a dozen commentaries, and co-chairs The Lancet Commission on women, power, and cancer. In 2022 she received the Humanitarian Award from the American Society of Clinical Oncology (ASCO).

John Kairalla is a Research Associate Professor and Associate Program Director of the Children’s Oncology Group, Statistics and Data Center-Gainesville in the Department of Biostatistics at the University of Florida. He received his PhD in Biostatistics from the University of North Carolina at Chapel Hill. His current research focus is in clinical trial design, development, monitoring, and analysis with applications in childhood cancer research with a focus on late phase pediatric Acute Lymphoblastic Leukemia (ALL) trials.

Dr Sreekumaran Nair has thirty three years of experience in biostatistics with extensive experience in post PhD teaching, research and mentoring in the medical college/health science/public health/medical university setting. He presently leads the Biostatistics Masters, Doctoral and Research Leadership mentoring programme at JIPMER, Puducherry.

Richard Chairs the UK’s Cancer Research Advocates Forum and is the former Chair of the Stakeholder Forum at BBMRI-ERIC (the European biobanking collaboration). He was the patient co-author of the 2015 Cancer Strategy for England, an advisor to the UK government during the early stages of the Covid pandemic, and to the European Parliament on the GDPR legislation. He helped develop patient involvement in NIHR, and helped found the AllTrials campaign and the useMYdata movement, which he currently also Chairs. He is the founding co-Editor-in-Chief of BMC’s Journal of Research Involvement and Engagement.

In his twenty-six years as a patient advocate, Richard has been involved with over 100 research studies and programmes. He works with many research charities and institutions, with patient groups and advocates in Europe, Africa, Canada and the USA, and with industry, from start-ups to Big Pharma. He is the longest-serving patient partner at Genomics England and at Cancer Research UK, where he has uniquely sat on all funding committees, as well as on both the Cancer Grand Challenge Advocacy Advisory Panel and on a CGC project.

Richard’s professional life included successful careers in education, journalism and local government. His ambition is to spend more time sitting on beaches reading history books.

Dr Devidas earned a PhD in Applied Statistics from the University of Memphis and spent the ensuing 32 years as a faculty member at UCLA, University of Mississippi Medical Center and University of Florida. She brings more than 25 years of experience in the field of pediatric oncology. She is Director of Analytics in the Department of Global Pediatric Medicine at St Jude Children’s Research Hospital. She and her team provide biostatistical and analytic support for the various global initiatives/research projects in the department. She is a member of the graduate faculty and a faculty in the St Jude Global Academy. She is the study statistician for clinical trials run by the North American Consortium for Histiocytosis (NACHO), a consortium dedicated to the development and implementation of clinical and translational studies and biological research for histiocytic diseases. She is also the study statistician for a trial studying gene therapy for Hemophilia B in low-middle income countries, conducted by St Jude Children’s Research Hospital. Dr Devidas is the Lead Statistician for the Acute Lymphoblastic Leukemia (ALL) biology/therapeutic clinical trials in the NCI sponsored (National Clinical Trials Network) international cooperative group, the Children’s Oncology Group (COG). She is PI, Co-PI and co-investigator on several current and past NIH grants supporting clinical research. Her methodological research has focused on statistical issues related to the design and conduct of clinical studies. .

Caitlyn Duffy, MD is a pediatric oncologist and Global Oncology Fellow at St. Jude Children’s Research Hospital in the Department of Global Pediatric Medicine. She graduated from the Medical College of Georgia and completed her Pediatrics Residency at Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center in Nashville, TN. She completed Pediatric Hematology and Oncology Fellowship at St. Jude Children’s Research Hospital. Dr Duffy’s is a clinician and research scientist with a focus on acute lymphoblastic leukemia and using implementation science to improve delivery of pediatric cancer care on a global scale. She completed additional training at the National Cancer Institute: Training Institute for Dissemination and Implementation Research in Cancer and will graduate from Johns Hopkins Bloomberg School of Public Health with a Master of Public Health and Global Health Certificate in May 2023. Dr. Duffy is a core member of the SJCRH-Washington University in St. Louis (WUSTL) Implementation and Dissemination Science Global Working Group, which is part of a broader SJCRH-WASH-U research collaborative. She is also a co-founder and co-lead of the SIOP Young Investigator LMIC working group and SIOP Global Health Steering Committee member.

Carlos Rodriguez-Galindo, MD, serves as director of St. Jude Global and chair of the Department of Global Pediatric Medicine. He is also an executive vice president and director of the St. Jude WHO Collaborating Centre for Childhood Cancer. Rodriguez-Galindo is leading an effort by St. Jude to ensure childhood cancer patients have access to quality care no matter where they live. The St. Jude Global program has established partnerships with more than 200 hospitals in close to 70 countries, which form the St. Jude Global Alliance. In addition to his work in global health, Dr. Rodriguez-Galindo’s areas of clinical research and expertise include retinoblastoma, sarcomas, rare cancers, and histiocytic disorders. He has been the chair of the Rare Tumor’s committee of the Children’s Oncology Group and the President of the Histiocyte Society, and has been the principal investigator of several institutional, national, and international trials.

Satish Gopal, M.D., M.P.H. was appointed Director of the Center for Global Health (CGH) at the National Cancer Institute (NCI) in 2020. In this role, he oversees the development of initiatives and collaborations with other NCI and NIH partners, NCI-designated cancer centers, and other governmental and non-governmental organizations to support cancer research, promote science-based cancer control, and build research capacity in low- and middle-income countries. Before coming to NCI, Dr. Gopal was the Cancer Program Director for the University of North Carolina collaboration with the Malawi Ministry of Health.

Dr. Gopal earned his medical degree from the Duke University School of Medicine in 2001. He completed training in internal medicine and pediatrics at the University of Michigan, lived and worked in Tanzania from 2007 to 2009, then returned to the United States to pursue medical oncology and infectious disease training at the University of North Carolina. He lived with his family in Malawi from 2012 to 2019, when he was the only medical oncologist in the country and treated public sector cancer patients at the national teaching hospital alongside Malawian colleagues. He returned frequently to provide clinical service in the North Carolina Cancer Hospital.

As an extramural physician-scientist, his NIH-funded research program focused on epidemiologic, clinical, and translational studies of lymphoma and HIV-associated malignancies in Africa and he oversaw a multidisciplinary cancer research portfolio which sought to address many of the commonest cancers in the region, including cervical, breast, and esophageal cancer. This program generated some of the first published studies in Africa to describe detailed molecular profiles for specific cancer types, characterize several unique lymphoproliferative disorders, report clinical trials of targeted cancer therapy, perform economic evaluations of cancer treatment, and integrate patient-reported outcome measurements. He has authored more than 100 publications in journals such as NEJM, JAMA, Lancet, and Nature Medicine among others, and mentored more than 30 early-career U.S. and African pre- and post-doctoral cancer researchers, many of whom hold academic positions in global oncology at NCI-designated cancer centers, African academic institutions, and other international organizations. He has spoken widely and provided leadership and expertise on various working groups, review committees, and boards. He previously served as the Associate Chair for African International Sites for the NCI AIDS Malignancy Consortium (AMC) with oversight responsibility for the network’s African clinical trials. He currently serves as the US representative on the Scientific Council for the International Agency for Research on Cancer (IARC).

Vishal Deo has completed his PhD in Statistics from the University of Delhi. He has significant research expertise in the fields of Biostatistics, Survival Modelling, Epidemiological Modelling, and their applications in Health Economics. He has great interest in Bayesian predictive modelling, growth curve and functional data analysis, and time-series modelling. He is proficient in R programming, STATA and MATLAB. His current areas of health research include estimation of HIV/AIDS epidemic burden, economic burden of non-communicable diseases, social determinants of health, covid-19 epidemiology and survivability, among others

Julie R. Gralow, MD, is Executive Vice President and Chief Medical Officer for the American Society of Clinical Oncology (ASCO). She is a breast medical oncologist and Professor (emeritus) of Medical Oncology at the University of Washington (UW) School of Medicine, where she served >25 years on faculty directing the Breast Medical Oncology program, as well as Affiliate Professor of Global Health. Dr. Gralow has extensive experience in conducting clinical trials, and is the former Executive Officer for Breast and Lung Cancer and Vice Chair of the Breast Cancer Committee for the SWOG Cancer Clinical Trials Network. Dr. Gralow is committed to improving the quality of life for cancer patients, and is co-Founder of Team Survivor Northwest, a non-profit aimed at helping female cancer survivors improve their health through fitness and exercise. Dr. Gralow founded the Women’s Empowerment Cancer Advocacy Network (WE CAN) to support cancer advocacy and education in low- and middle-income countries. She received the 2018 ASCO Humanitarian Award and the 2021 OncLive Giants of Cancer Care Award for Community Outreach/Policy for her work in empowering women cancer patients globally.

Victor M. Santana, MD is a full member in the Department of Oncology and the Department of Global Pediatric Medicine at St. Jude Children’s Research Hospital (SJCRH) and holds the Charles B. Pratt Endowed Chair in Solid Tumor Research. His professional career as a pediatric oncologist and clinical investigator has been devoted to developing new experimental treatment approaches for children with high-risk cancers and applying knowledge and expertise in clinical trial design and regulatory aspects of pediatric clinical research. His research aims to identify promising new therapies for children with cancer and understanding how they can be best implemented globally. As a clinical investigator for more than 35 years, Dr. Santana has been a principal investigator and collaborator in numerous clinical trials. Dr. Santana is a past member of the U.S. Food and Drug Administration’s Pediatric Advisory Committee, and presently serves on the NCI’s Central Pediatric Institutional Review Board (CIRB) and the NCI Clinical Trials and Translational Research Advisory Committee (CTAC). Dr. Santana is a past Chair of the Children’s Oncology Group Phase I-II Data Safety Monitoring Board, as well as past chair of the NCI Pediatric Central IRB. Dr. Santana’s interest in teaching the next generation of clinical investigators and staff is evidenced in his active participation as lecturer in the SoCRA Clinical Science course, and as a recipient of the organization’s President’s Award for Distinguished Service. Within the St. Jude Graduate School in Biomedical Sciences, he co-leads the master’s degree program in clinical investigations. To this workshop he brings expertise in understanding conceptual development, implementation strategies and solutions to challenges inherent in clinical research in international settings.

Angela is a medical statistician who has worked in health research for over 30 years beginning her career in cancer clinical trials in the early 1990s. She has worked across a range of disease areas and settings working in industry as well as the national health service. Angela joined the MRC Clinical Trials Unit in 2007 as a senior statistician for a large HIV prevention trial and since then has moved to tuberculosis and currently co-leads the respiratory infections programme. Angela has an MSc in medical statistics from the London School of Hygiene and Tropical Medicine and a PhD from Imperial College, London.

Shital completed her undergraduate studies (BSc in Biological Sciences from Rutgers University) and went on to do her Master’s in Microbiology and Molecular Genetic with research at the Cancer Institute of New Jersey in the US. Yearning for clinical experience, she attended medical school in the UK for her MD. Interested in public health, she moved to India to work in the not-for-profit sector. She worked with Cancer Patients Aid Association and Americares India. Her worked with various local and international NGOs entailed lifestyle disease awareness and education, infection prevention and control, healthcare worker safety programmes for government hospitals. She is also an anti-tobacco activist and has devoted her time to counsel cancer patients, conduct awareness programmes for children in schools and advocate against tobacco companies. Since 2013, she has been associated with PatientsEngage, a patient enterprise that works towards educating, engaging, and empowering patients and their care providers with chronic illnesses. As a medical advisor and Project Head, she works with various stakeholders to better the lives of patients and advocate for numerous issues.